Autologous hematopoietic stem cell transplantation for patients with diffuse large B-cell lymphoma: a retrospective study / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 617-622, 2013.
Article
em Zh
| WPRIM
| ID: wpr-332725
Biblioteca responsável:
WPRO
ABSTRACT
The purpose of this study was to investigate the efficacy of autologous hematopoietic stem cell transplantation (auto-HSCT) for patients with diffuse large B-cell lymphoma (DLBCL), and analyse the factors influencing prognosis. The clinical data of 67 patients with DLBCL received auto-HSCT from 1996 to 2011 and cumulative overall survival (OS), progression-free survival (PFS), transplant-related mortality (TRM), and relapse rate were retrospectively analyzed. The results showed that the median follow-up time was 40 months after transplantation. Three-year cumulative OS and PFS were 70.6% and 66.4% respectively, 5-year cumulative OS and PFS were 70.6% and 63.8% respectively, and TRM was 7.2%. One-year and three-year cumulative relapse rate were 16.5% and 23.7% respectively. Univariate analysis revealed that the age and pre-transplant disease status were significantly associated with poor prognosis (P < 0.05). It is concluded that auto-HSCT is a safe and effective therapeutic option for patients with DLBCL, especially for the young patients or patients with better remission.
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Prognóstico
/
Terapêutica
/
Transplante Autólogo
/
Taxa de Sobrevida
/
Estudos Retrospectivos
/
Mortalidade
/
Linfoma Difuso de Grandes Células B
/
Resultado do Tratamento
/
Transplante de Células-Tronco Hematopoéticas
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Adolescent
/
Adult
/
Child
/
Female
/
Humans
/
Male
Idioma:
Zh
Revista:
Journal of Experimental Hematology
Ano de publicação:
2013
Tipo de documento:
Article